Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -3.23% is 256% below its 4-year average of 2.07%, near the low end of its 4-year range (-9.63%–19.44%).
As of the fiscal period ended Tuesday, September 30, 2025.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-03-31): -7.06%.
RETURN ON ASSETS (ROA)
-3.23%
RETURN ON ASSETS (ROA) AVG TTM
N/A
RETURN ON ASSETS (ROA) AVG 3Y
-4.16%
RETURN ON ASSETS (ROA) AVG 5Y
2.07%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
+22.42%
CURRENT VS 5Y AVG
-256.19%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+89.98%
vs the sector median at left
WORK Medical Technology Group Ltd. Class A
Market Cap
$3.63M
Return on Assets (ROA)
-3.23%
TTM Avg
N/A
3Y Avg
-4.16%
5Y Avg
2.07%
Market Cap
$3.65M
Return on Assets (ROA)
-194.09%
TTM Avg
-543.36%
3Y Avg
-310.28%
5Y Avg
-256.27%
Market Cap
$3.65M
Return on Assets (ROA)
-67.51%
TTM Avg
-41.84%
3Y Avg
-44.47%
5Y Avg
-41.13%
Market Cap
$3.53M
Return on Assets (ROA)
-206.55%
TTM Avg
-205.58%
3Y Avg
-343.02%
5Y Avg
-343.02%
Market Cap
$3.50M
Return on Assets (ROA)
-8.01%
TTM Avg
-37.73%
3Y Avg
-92.58%
5Y Avg
-74.07%
Market Cap
$3.49M
Return on Assets (ROA)
-19.43%
TTM Avg
-90.07%
3Y Avg
-138.72%
5Y Avg
-110.42%
Market Cap
$3.90M
Return on Assets (ROA)
-189.43%
TTM Avg
-137.65%
3Y Avg
-200.06%
5Y Avg
-203.62%
Market Cap
$3.93M
Return on Assets (ROA)
-181.89%
TTM Avg
-125.13%
3Y Avg
-74.22%
5Y Avg
-63.39%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| WORK Medical Technology Group Ltd. Class A (WOK) | $3.63M | -3.23% | N/A | -4.16% | 2.07% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.65M | -194.09% | -543.36% | -310.28% | -256.27% |
| Evogene Ltd. (EVGN)vs › | $3.65M | -67.51% | -41.84% | -44.47% | -41.13% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.53M | -206.55% | -205.58% | -343.02% | -343.02% |
| Moolec Science S.A. (MLEC)vs › | $3.50M | -8.01% | -37.73% | -92.58% | -74.07% |
| Eocene Ltd. (EOCN)vs › | $3.50M | N/A | N/A | N/A | N/A |
| Mustang Bio, Inc. (MBIO)vs › | $3.49M | -19.43% | -90.07% | -138.72% | -110.42% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $3.90M | -189.43% | -137.65% | -200.06% | -203.62% |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | -181.89% | -125.13% | -74.22% | -63.39% |
| Nexalin Technology, Inc. (NXL)vs › | $3.30M | -299.21% | -178.76% | -127.09% | -697.98% |
ROA
-3.2%
ROE
-5.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-09-30 | -3.23% |
| 2024-09-29 | -9.63% |
| 2023-09-29 | 0.37% |
| 2022-09-29 | 3.39% |
| 2021-09-29 | 19.44% |
| 2020-09-29 | 2.07% |
